Literature DB >> 8283949

[Is adjuvant chemotherapy of colon cancers (Dukes C; TxN+) regarded as standard today?].

E Farthmann1, C Herfarth, U Laffer, F Harder, P M Schlag, H Wilke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8283949     DOI： 10.1007/BF01876441

Source DB:  PubMed          Journal:  Langenbecks Arch Chir        ISSN： 0023-8236


× No keyword cloud information.
  7 in total

Review 1.  Adjuvant therapy for colon and rectal cancer. NIH Consensus Development Conference.

Authors:  U Metzger
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

2.  Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients.

Authors:  F Lindemann; G Schlimok; P Dirschedl; J Witte; G Riethmüller
Journal:  Lancet       Date:  1992-09-19       Impact factor: 79.321

3.  Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer.

Authors:  R Windle; P R Bell; D Shaw
Journal:  Br J Surg       Date:  1987-07       Impact factor: 6.939

Review 4.  Adjuvant therapy of colorectal cancer. Why we still don't know.

Authors:  M Buyse; A Zeleniuch-Jacquotte; T C Chalmers
Journal:  JAMA       Date:  1988-06-24       Impact factor: 56.272

5.  Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic.

Authors:  J A Laurie; C G Moertel; T R Fleming; H S Wieand; J E Leigh; J Rubin; G W McCormack; J B Gerstner; J E Krook; J Malliard
Journal:  J Clin Oncol       Date:  1989-10       Impact factor: 44.544

6.  Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.

Authors:  C G Moertel; T R Fleming; J S Macdonald; D G Haller; J A Laurie; P J Goodman; J S Ungerleider; W A Emerson; D C Tormey; J H Glick
Journal:  N Engl J Med       Date:  1990-02-08       Impact factor: 91.245

7.  Adjuvant therapy of poor prognosis colon cancer with levamisole: results of an EORTC double-blind randomized clinical trial.

Authors:  J P Arnaud; M Buyse; B Nordlinger; F Martin; J C Pector; P Zeitoun; A Adloff; N Duez
Journal:  Br J Surg       Date:  1989-03       Impact factor: 6.939
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.